| Keywords: |
survival; treatment response; survival analysis; survival rate; clinical trial; cancer recurrence; intensity modulated radiation therapy; cisplatin; patient selection; note; gemcitabine; paclitaxel; adjuvant therapy; cancer adjuvant therapy; chemotherapy, adjuvant; radiotherapy, adjuvant; cancer staging; positron emission tomography; methodology; lymph node metastasis; antineoplastic agent; neoplasm staging; preoperative evaluation; metastasis; computer assisted tomography; multiple cycle treatment; neoplasm recurrence, local; lung non small cell cancer; lung resection; antineoplastic combined chemotherapy protocols; carcinoma, non-small-cell lung; lung neoplasms; pneumonectomy; editorial; pathology; lung tumor; survival time; disease severity; radiation dose fractionation; early diagnosis; tumor recurrence; adjuvant chemotherapy; remission; remission induction; thorax radiography; risk reduction; mediastinoscopy; endoscopic echography; mediastinum lymph node
|
